Abstract: In embodiments, a VDAX configured with an ecosystem security platform (ESP) and has a digital DNA assigned thereto that includes an eligibility object, a correlation object, and a differentiation object is disclosed. In embodiments, the ESP includes a DNA module configured to: manage and modify the DNA of the VDAX. The ESP also includes a link module that receives and decodes a link from a second VDAX that contains encoded GRI and decodes the encoded GRI based on the eligibility object and a modified correlation object. The ESP includes a sequence mapping module that maps a sequence from a first portion of a digital object to be provided to the second VDAX into a modified differentiation object modified using the GRI to obtain an engagement factor. The ESP includes a transformation module that generates a VBLS object by encoding a second portion of the digital object using the engagement factor.

Abstract: The disclosure provides a method of generating an artificial fluorescent image of cells is provided.

Abstract: According to some embodiments of the present disclosure, techniques for performing genomic security-related control of a digital ecosystem are disclosed. In embodiments, the digital ecosystem includes an ecosystem VDAX that maintains a progenitor genomic data set corresponding to the digital ecosystem, generates a plurality of respective progeny genomic data sets based on the progenitor genomic data set, and allocates the progeny genomic data set to a respective progeny VDAX of a plurality of progeny VDAXs, wherein the progeny VDAX establishes unique non-recurring engagements with other progeny VDAXs in the digital ecosystem based on the respective progeny genomic data set allocated to the progeny VDAX without any further interaction from the ecosystem VDAX.

Abstract: An infusion management platform can determine, based on one or more infusion events, whether to group infusions or segments of infusions. Related apparatus, systems, techniques and articles are also described.

Abstract: Techniques regarding autonomously controlling the delivery of one or more chemical compounds are provided. For example, one or more embodiments described herein can comprise a system, which can comprise a memory that can store computer executable components. The system can also comprise a processor, operably coupled to the memory, and that can execute the computer executable components stored in the memory. The computer executable components can comprise a compound component can identify a chemical compound mixture to be distributed to an entity based on a trust disposition value. The trust disposition value can be determined using machine learning technology and is indicative of an expected effectiveness of the chemical compound mixture with regards to the entity.

Abstract: A system for identifying and evaluating a pocket of a protein includes performing a Voronoi tessellation and developing a Voronoi diagram of a surface of the protein. All alpha-spheres on the surface of the protein are identified. The alpha-spheres are filtered based on radius and remaining alpha-spheres are clustered into alpha-clusters. At least one alpha-cluster is selected for quantitative evaluation. Alpha-sphere contact atoms are determined for a plurality of interaction points of the pocket. A Delaunay triangulation of the four contact atoms of each interaction point is performed. A plurality of alpha-spaces for each interaction point are determined. An alpha-atom and an alpha-atom contact surface area (ACSA) of each interaction point is determined. The pocket is ranked, a pocket-fragment complementarity is determined, and the pocket is matched between various conformations of the proteins.

Abstract: A method of diagnosing central nervous system injuries such as acquired brain injury (ABI) and/or acquired spinal cord injury (ASI), including mild TBI (concussion or blast wave), mild ASI (contusion, stretch or partial cord transection), non-TBI brain injury and/or non-TSI spinal cord injury in a subject (animal or human). The method includes (a) obtaining a biological test sample from the subject, identifying metabolites in the subject's sample using metabolomics thereby obtaining a subject's metabolite matrix and generating a subject's profile using the patient's metabolite matrix; and (b) using multivariate statistical analysis and machine learning to compare the subject's profile with predetermined set of profiles of CNS injuries and a predetermined set of profiles of controls to determine if the subject has a CNS injury.

Abstract: A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and/or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and/or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and/or quantitative assessment of T-cell receptor signaling, and the determined qualitative and/or quantitative assessment of mutation burden.

Abstract: Disclosed herein are methods and systems of utilizing sequencing reads for detecting and quantifying the presence of a tissue type or a disease type in cell-free DNA prepared from blood samples.

Abstract: The present invention relates to extraction of a signal for a target nucleic acid sequence from signals for two target nucleic acid sequences in a sample. The present invention can contribute to dramatic improvement in methods for detecting target nucleic acid sequences using different detection temperatures and reference values. The present invention using an amended reference value as well as an initial reference value can lead to increasing the detection accuracy in methods for detecting target nucleic acid sequences using different detection temperatures and reference values.

Abstract: Embodiments of methods, systems, and tangible non-transitory computer readable medium having instructions are presented. A method includes calculating a plurality of feature values for a number of bioinformatic features of the desired hybridization reaction; and calculating distances between the plurality of feature values and corresponding database rate constant values stored in a database, the database comprising a plurality of hybridization reactions having known rate constants. The method additionally includes calculating a weighted average of a logarithm of the database rate constant values, with larger weights assigned to value instances having values lower in distance to the plurality of feature values of the desired hybridization reaction; and providing the weighted average as a predicted logarithm of the rate constant of the desired hybridization reaction.

Abstract: Processes are provided for detecting loss of heterozygosity of Human Leukocyte Antigen (HLA) in a subject using analysis of next generation sequencing (NGS) data. The processes include aligning NGS data and identifying unmapped and mapped reads, updating reference data, and feeding one or more sequence reads to an HLA typing process for identifying candidate HLA alleles and feeding HLA type data to a loss of heterozygosity (LOH) modeling process for determining a LOH status for each HLA allele. A report may be generated of the LOH statuses for each of HLA allele.

Abstract: Systems and method for identifying somatic mutations can receive first and second sequence information, determine if a variant present in the first sequencing information is also present in the second sequence information, and identify variants present in the first sequence information are somatic mutations when the variant is either not present in the second sequence information or the presence of the variant in the second sequence information is likely due to a sequencing error.

Abstract: Disclosed herein are system, method, and computer program product embodiments for optimizing the determination of a phenotypic impact of a molecular variant identified in molecular tests, samples, or reports of subjects by way of regularly incorporating, updating, monitoring, validating, selecting, and auditing the best-performing evidence models for the interpretation of molecular variants across a plurality of evidence classes.

Abstract: The present disclosure provides a group of diagnostic biomarkers usable for diagnosis of colorectal cancer or colorectal adenoma. A method for detecting colorectal cancer or colorectal adenoma using the group of diagnostic biomarkers is also provided. For example, the method provided by the present disclosure is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage).

Abstract: The instant invention provides workflows for the design and characterization of mechanism-based sirtuin modulating compounds, including new or improved sirtuin activating compounds. Workflows for the design of mechanism-based sirtuin activating compounds are provided, based on conditions that must be satisfied by activators if they are to exploit the common catalytic mechanism of all sirtuin enzymes and hence increase catalytic efficiency for any sirtuin and any substrate.

Abstract: A cancer prediction engine receives a digital image of a tissue biopsy stained for a presence of a biomarker associated with a presence of cancer in the tissue, determines a set of color attribute values of a color space for each pixel of the digital image, classifies, in view of the color attribute values, each pixel of the digital image between a first subset of pixels depicting tissue and a second subset of pixels not depicting tissue, determines whether the digital image depicts cancerous tissue in view of a number of pixels in the second subset of pixels, and responsive to determining that the digital image depicts cancerous tissue, determines a predicted cancer stage for the digital image of the tissue biopsy based at least in part on a color intensity category associated with the color attribute values for each pixel of the first subset of pixels.

Abstract: Provided is an apparatus for managing a player with a guard including a sensor sensing a vital information of a player to calculate an injury risk of the player to thereby manage a condition of the player, the apparatus including: a communication unit receiving the vital information from the guard and transmitting the injury risk to the guard; a memory storing a program calculating the injury risk to manage the condition of the player; and a processor connected to the communication unit and the memory to execute an operation implemented by the program, in which the program may include instructions using the vital information and pre-stored vital recovering ability data of the player to calculate the injury risk of the player.

Abstract: A system and method for detecting gene-environment interactions, a method of making predictions about individual response to a specific environmental factor with respect to a single phenotype and a simulation method determining the optimal parameters for use of the gene-environment interaction detection method. Gene-environment interaction detection and the discovery of previously unknown interactions are facilitated.

Abstract: The invention disclosed herein generally relates to methods of assessing and monitoring tumor load through analysis of tumor DNA in cancer patients. Quantitative measures derived from cell-free DNA and germline DNA are used to assess and monitor tumor load. By assessing and monitoring tumor load, cancer may be detected in a subject. The tumor load of a subject may be assessed at a number of different time points to monitor a progression, regression, or recurrence of cancer in a subject.